System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Mohamed Bouattour is an expert in Hepatology at Beaujon Hospital (France). As of October 2026, ScienceLeadR ranks Mohamed Bouattour in the top 1% of experts worldwide for Biliary Tract Neoplasms, Liver Neoplasms and Carcinoma. Mohamed Bouattour has authored 252 publications, the most recent in 2026, and is an investigator in 58 clinical trials, 30 of them ongoing. SLR score: 1,671 (community average: 125). How the SLR is computed.

LeadR Profile

Mohamed Bouattour Beaujon Hospital France
1 671 ScienceLeadR Reputation 1671

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Oncology - Gastroenterology - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Beaujon Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 252

Citations

Citations: 8 784 1st author: 18 Last author: 14 Unique author: 0

Main journals

J Hepatol 34
J Clin Oncol 32
Ann Oncol 24
JHEP Rep 16
Dig Liver Dis 9

Best Journals

Ann Oncol 20
J Clin Oncol 19
J Hepatol 18

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial.
PMID 42898854 — biliary tract neoplasms, safety, neoplasms, biliary tract, therapeutics		EClinicalMedicine20260
Current Perspectives on the Use of Adjuvant Pembrolizumab for Hepatocellular Carcinoma.
PMID 42764956 — cells, carcinoma, hepatocellular, neoplasms, neoplasm, residual, therapeutics		J Hepatocell Carcinoma20260
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
PMID 42736101 — carcinoma, hepatocellular, safety, neoplasms, drug therapy, tumor burden, chemotherapy		Dig Liver Dis20260
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
PMID 42636832 — carcinoma, hepatocellular, progression-free survival, neoplasms, drug-related side effects and adverse reactions, therapeutics		Lancet Oncol Top journal20260
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).
PMID 42562579 — quality of life, neoplasms, liver, liver neoplasms, ambulatory care, therapeutics		BMJ Open20260

Clinical Studies 58

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 2 19
Phase 3 18
N/A 14
Phase 1/Phase 2 3
Phase 2/Phase 3 3
Phase 1 1

By status:

Recruiting 24
Completed 19
Active not recruiting 10
Terminated 2
Unknown 2
Not yet recruiting 1

By type:

Interventional 52
Observational 6

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 3
multicentric5to9 10
multicentricup10 38

Main Topics

Ongoing Clinical Trials

30 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1 Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB B2033 Alone or in Combination With Tislelizumab With or Without Bevacizumab in Participants With Selected Advanced or Metastatic Solid Tumors
2025-524136-19-00 — safety, neoplasms, bevacizumab, pharmacokinetics		Phase 1Recruiting2026
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Evaluation of the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab
2022-502948-13-00 — carcinoma, hepatocellular, safety, immune checkpoint inhibitors, carcinoma		Phase 2Active not recruiting2024
MICROBIOTA MODIFICATION FOR IMMUNO ONCOLOGY IN HEPATOCELLULAR CARCINOMA MOTHER
2023-508201-25-00 — carcinoma, hepatocellular, mothers, microbiota, carcinoma		Phase 2Recruiting2025
Evaluation of Multiparametric dynamic whole body 68Ga PSMA PET imaging for Hepatocellular Carcinoma recurrence HIMIKO study
2024-515178-28-00 — carcinoma, hepatocellular, positron-emission tomography, carcinoma		Phase 1/Phase 2Recruiting2025
TACTIC MP0317 A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY
2024-520029-35-01 — neoplasms, maintenance, biliary tract, therapeutics, carcinoma		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS